# Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

> **NCT01238042** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Barrett's Esophagus
- CIS
- HGD

## Interventions

- **DRUG:** HPPH

## Key facts

- **NCT ID:** NCT01238042
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2004-10
- **Final completion:** 2014-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238042, "Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01238042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*